RxDoctor Payments Data

Sandra Garofalo, APRN

Gerontology · Indianapolis, INNPI 1689221905

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (36.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 55 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 43.4% of the total. 2025 is the largest year on record at $11,887, more than ten times the $242 reported in 2021. Among gerontology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$23,832in general payments, 2019–2025

Across 283 payments — averaging $84.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$10K
  • Regeneron$3K
  • Novartis$2K
  • Genentech USA, Inc.$2K
  • AstraZeneca$804
  • Incyte Corporation$654
  • plus $6K from 49 others

What the payments were for

  • Consulting fees$2,74812%
  • Speaking & faculty fees$7,20330%
  • Travel & lodging$3,53415%
  • Food & beverage$8,72037%
  • Education$3481%
  • Other$1,2805%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,832 in reported general payments places this provider in the 95th percentile of 230 gerontology providers in Indiana.

See all gerontology providers in Indiana

Medicare billing

Part B allowed, 2024
$83,115
Medicare patients
362
Services billed
1,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$20,421
Anastrozole233$5,160
Exemestane11$2,641
Tamoxifen Citrate49$1,745
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen35$1,334
Letrozole64$1,311
Ondansetron Hcl44$1,224
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine37$842
Oxycodone Hcl39$719
Dexamethasone14$494
Lidocaine12$364
Acyclovir15$245
Omeprazole12$226
Vitamin D2Ergocalciferol (Vitamin D2)16$225
Prochlorperazine Maleate23$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$425$20,42117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 230 gerontology providers in Indiana.

Other gerontology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →